{
    "symbol": "IMVT",
    "quarter": 4,
    "year": 2022,
    "date": "2022-06-09 11:58:04",
    "content": "  These forward-looking statements include, among other things, statements regarding Immunovant\u2019s plan to initiate two Phase 3 clinical trials for batoclimab in TED in the second half of calendar year 2022, with an expected topline data readout in the first half of calendar year 2025, and its plan to initiate a Phase 3 clinical trial in MG by the end of June 2022 with an expected readout in the second half of calendar year 2024; Immunovant\u2019s plans to develop batoclimab across a broad range of autoimmune indications; the potential efficacy and safety of Immunovant\u2019s product candidate; Immunovant\u2019s expectations regarding the timing, design and results of its clinical trials, including the timing of future data readouts; and the announcement of additional indications, and whether if approved batoclimab will be successfully distributed, marketed, and commercialized."
}